The drug is highly cardioselective at 5 mg. In addition, at doses above 10 mg, nebivolol loses its cardioselectivity and blocks both β1 and β2 receptors, while the recommended starting dose of nebivolol is 5 mg, sufficient control of blood pressure may require doses up to 40 mg.
The medication exhibits strong preference for β1 receptors at 5 mg. Furthermore, at doses exceeding 10 mg, nebivolol ceases to be cardioselective and blocks both β1 and β2 receptors, whereas the initial recommended dose of nebivolol is 5 mg, which may necessitate higher doses up to 40 mg for effective blood pressure management.